Celgene, Accord Healthcare Resolve Revlimid Patent Dispute -- Update
July 05 2018 - 4:57PM
Dow Jones News
By Maria Armental
Celgene Corp. (CELG) and Accord Healthcare Ltd. have resolved
patent claims over Celgene's leading product, blood-cancer drug
Revlimid.
Under the terms of the settlement, Accord has agreed to vacate
challenges to Celgene's patents, Celgene said Thursday in a
securities filing. Also, Celgene granted Accord the ability to
market a generic version of Revlimid, the drug lenalidomide, for
certain conditions as soon as early 2022, before Celgene's patents
and other restrictions in the U.K. and other European countries
expire.
Other terms of the settlement weren't disclosed.
The deal effectively protects Celgene's Revlimid sales through
early 2022. In its annual report filed with the Securities and
Exchange Commission in February, Celgene had guided for European
protection "through at least 2022."
Revlimid, the company's flagship cancer treatment, accounted for
more than half of its $13 billion revenue in the most recent
year.
This year, Celgene expects Revlimid net sales to reach $9.5
billion, up from $8.19 billion in 2017.
In 2015, Celgene reached a similar settlement with Natco Pharma
Ltd., allowing the Indian drug maker to sell a limited amount of
the generic version of Revlimid in March 2022.
Accord, one of the fastest-growing generic pharmaceutical
companies in the U.K. and Ireland, sued Celgene in the U.K. last
year. The matter was slated to go to trial this year.
Celgene shares, down 23% this year, were slightly down in
after-hours trading.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
July 05, 2018 17:42 ET (21:42 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024